This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

IceCure Medical Toekomstige groei

Future criteriumcontroles 2/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor IceCure Medical te voorspellen.

Belangrijke informatie

32.8%

Groei van de winst

n/a

Groei van de winst per aandeel

Medical Equipment winstgroei	22.3%
Inkomstengroei	47.5%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	24 Jul 2023

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

TASE:ICCM - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2025	36	-1	-13	N/A	2
12/31/2024	11	-14	-21	N/A	4
12/31/2023	5	-16	-17	-15	4
3/31/2023	3	-16	-15	-14	N/A
12/31/2022	3	-17	-15	-14	N/A
9/30/2022	4	-16	-17	-16	N/A
6/30/2022	4	-15	-17	-16	N/A
3/31/2022	3	-13	-14	-14	N/A
12/31/2021	4	-10	-13	-13	N/A
9/30/2021	4	-8	-9	-8	N/A
6/30/2021	4	-6	-7	-6	N/A
3/31/2021	4	-4	-5	-5	N/A
12/31/2020	4	-4	-4	-4	N/A
9/30/2020	3	-4	-2	-2	N/A
6/30/2020	3	-4	-1	0	N/A
3/31/2020	2	-4	-1	-1	N/A
12/31/2019	2	-5	-2	-2	N/A
9/30/2019	1	-5	N/A	N/A	N/A
6/30/2019	1	-4	-4	-4	N/A
3/31/2019	1	-4	-4	-4	N/A
12/31/2018	1	-4	-3	-3	N/A
9/30/2018	1	-3	N/A	N/A	N/A
6/30/2018	1	-3	-3	-3	N/A
3/31/2018	1	-3	-3	-3	N/A
12/31/2017	1	-3	-3	-3	N/A
9/30/2017	1	-3	-3	-3	N/A
6/30/2017	1	-3	-3	-3	N/A
3/31/2017	1	-3	-3	-3	N/A
12/31/2016	1	-3	N/A	-3	N/A
9/30/2016	1	-3	N/A	-3	N/A
6/30/2016	1	-4	N/A	-4	N/A
3/31/2016	1	-4	N/A	-3	N/A
12/31/2015	1	-4	N/A	-3	N/A
9/30/2015	1	-4	N/A	-3	N/A
6/30/2015	1	-4	N/A	-3	N/A
3/31/2015	1	-4	N/A	-3	N/A
12/31/2014	1	-5	N/A	-3	N/A
9/30/2014	1	-5	N/A	-4	N/A
6/30/2014	1	-5	N/A	-4	N/A
3/31/2014	0	-5	N/A	-3	N/A
12/31/2013	0	-5	N/A	-3	N/A
9/30/2013	0	-5	N/A	-4	N/A
6/30/2013	0	-5	N/A	-4	N/A
3/31/2013	0	-5	N/A	-4	N/A
12/31/2012	0	-5	N/A	-4	N/A
9/30/2012	0	-4	N/A	-4	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat ICCM de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat ICCM de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat ICCM de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van ICCM ( 47.5% per jaar) zal naar verwachting sneller groeien dan de markt IL ( 1.9% per jaar).

Hoge groei-inkomsten: De omzet van ICCM ( 47.5% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ICCM naar verwachting over 3 jaar hoog zal zijn

This company listing is no longer active

IceCure Medical Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Will IceCure Medical (TLV:ICCM) Spend Its Cash Wisely?

New major risk - Financial position

New major risk - Revenue and earnings growth

IceCure Medical Ltd to Report Q1, 2023 Results on May 22, 2023

Insufficient new directors

Full year 2022 earnings released: US$0.46 loss per share (vs US$0.35 loss in FY 2021)

Here's Why We're Watching IceCure Medical's (TLV:ICCM) Cash Burn Situation

IceCure Medical Ltd Receives Notice of Allowance from the U.S. Patent and Trademark Office for Its Patent Application Titled Cryogen Pump

IceCure Medical Ltd Receives Notice of Patent Allowance in Japan for A Novel Cryogenic Pump for Its Next-Generation Cryoablation Systems

IceCure Medical Ltd Announces Interim Results from the ICESECRET Study for the Treatment of Patients with Small Renal Masses

IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.091 loss in 3Q 2021)

IceCure Medical Ltd to Report Nine Months, 2022 Results on Dec 05, 2022

IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures

IceCure Medical Ltd. Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery

Are Investors Undervaluing IceCure Medical Ltd (TLV:ICCM) By 29%?

IceCure Medical Ltd Submits Regulatory Filing in Vietnam for Approval of Prosense®

Second quarter 2022 earnings released

IceCure Medical Ltd to Report Q2, 2022 Results on Aug 15, 2022

IceCure Medical Ltd Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors

IceCure Medical Ltd to Report Q1, 2022 Results on May 18, 2022

Full year 2021 earnings released: US$0.35 loss per share (vs US$0.27 loss in FY 2020)

Is IceCure Medical Ltd (TLV:ICCM) Potentially Undervalued?

IceCure Medical Ltd, Annual General Meeting, Mar 03, 2022

Icecure Medical Ltd Medical Receives Notice of Intention to Grant A European Patent Covering Its Cryogenic Pump

Is IceCure Medical (TLV:ICCM) In A Good Position To Deliver On Growth Plans?

IceCure Medical's Interim Results of the ICE3 Clinical Trial for Early-Stage Breast Cancer Cryoablation featured at the 2021 Annual Meeting of the Radiological Society of North America

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Icecure Medical Announces First Peer Reviewed Publication for the 3-Year Interim Analysis of the Ice3 Trial on Cryoablation of Low-Risk, Early-Stage Breast Cancer

Icecure Medical Ordinary Shares Deleted from Other OTC

IceCure Medical Ltd. Announces Positive Interim Results from ICE3 Clinical Trial for Breast Cancer Treatment by Freezing with the ProSense® Cryoablation System Presented at the 2021 ASBrS Meeting

Full year 2020 earnings released: ₪0.11 loss per share (vs ₪0.15 loss in FY 2019)

IceCure Signs Exclusive Distribution Agreement with Rise General Trading, LCC, Expanding Market Reach Across the Middle East

New 90-day high: ₪1.48

New 90-day high: ₪0.70

IceCure Medical Ltd Inks Expanded Distribution Agreement with Terumo Corporation for Thailand

New 90-day high: ₪0.72

IceCure Medical Ltd Expands Strategic Collaboration with Terumo Corporation, New Commercial Distribution Agreement Potentially Valued at over $7.0 Million

IceCure Medical Ltd has completed a Follow-on Equity Offering in the amount of ILS 20.7 million.

New 90-day low - ₪0.52

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven